MA39085B1 - Combination of cineol and amoxicillin for use in the treatment of a bacterial infection - Google Patents

Combination of cineol and amoxicillin for use in the treatment of a bacterial infection

Info

Publication number
MA39085B1
MA39085B1 MA39085A MA39085A MA39085B1 MA 39085 B1 MA39085 B1 MA 39085B1 MA 39085 A MA39085 A MA 39085A MA 39085 A MA39085 A MA 39085A MA 39085 B1 MA39085 B1 MA 39085B1
Authority
MA
Morocco
Prior art keywords
combination
cineol
amoxicillin
treatment
bacterial infection
Prior art date
Application number
MA39085A
Other languages
French (fr)
Other versions
MA39085A1 (en
Inventor
Remmal Adnane
Amin Akhmouch Ahmed
Original Assignee
Advanced Scient Developements
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Scient Developements filed Critical Advanced Scient Developements
Priority to MA39085A priority Critical patent/MA39085B1/en
Priority to MA044286A priority patent/MA44286A/en
Priority to JP2019515760A priority patent/JP7033586B2/en
Priority to BR112018074913-3A priority patent/BR112018074913B1/en
Priority to CN201780041549.7A priority patent/CN109562182A/en
Priority to EP17743405.7A priority patent/EP3463479A2/en
Priority to US16/306,262 priority patent/US11872216B2/en
Priority to CA3026323A priority patent/CA3026323A1/en
Priority to PCT/MA2017/000014 priority patent/WO2017209588A2/en
Priority to EA201892808A priority patent/EA201892808A1/en
Publication of MA39085A1 publication Critical patent/MA39085A1/en
Publication of MA39085B1 publication Critical patent/MA39085B1/en
Priority to US18/408,636 priority patent/US20240148702A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une combinaison de cinéol et d' amoxicilline pour une utilisation dans le traitement d'une infection bactérienne chez un sujet. La présente combinaison peut en outre comprendre un inhibiteur de p-lactamases, de préférence de l'acide clavulanique. La combinaison selon l'invention permet en particulier de lutter contre les infections causées par des bactéries résistantes aux antibiotiques, de préférence aux antibiotiques de la famille des p-lactamines.The present invention relates to a combination of cineol and amoxicillin for use in the treatment of a bacterial infection in a subject. The present combination may further comprise an β-lactamase inhibitor, preferably clavulanic acid. The combination according to the invention makes it possible in particular to fight against infections caused by bacteria resistant to antibiotics, preferably antibiotics of the β-lactam family.

MA39085A 2016-06-02 2016-06-02 Combination of cineol and amoxicillin for use in the treatment of a bacterial infection MA39085B1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
MA39085A MA39085B1 (en) 2016-06-02 2016-06-02 Combination of cineol and amoxicillin for use in the treatment of a bacterial infection
EP17743405.7A EP3463479A2 (en) 2016-06-02 2017-06-02 Pharmaceutical formulation comprising cineol and amoxicillin
JP2019515760A JP7033586B2 (en) 2016-06-02 2017-06-02 Pharmaceutical product containing cineole and amoxicillin
BR112018074913-3A BR112018074913B1 (en) 2016-06-02 2017-06-02 PHARMACEUTICAL FORMULATION OF CINEOL AND AMOXICILLIN
CN201780041549.7A CN109562182A (en) 2016-06-02 2017-06-02 Pharmaceutical preparation comprising cineole and Amoxicillin
MA044286A MA44286A (en) 2016-06-02 2017-06-02 PHARMACEUTICAL FORMULATION OF CINEOL AND AMOXICILLIN
US16/306,262 US11872216B2 (en) 2016-06-02 2017-06-02 Pharmaceutical formulation comprising cineole and amoxicillin
CA3026323A CA3026323A1 (en) 2016-06-02 2017-06-02 Pharmaceutical formulation comprising cineol and amoxicillin
PCT/MA2017/000014 WO2017209588A2 (en) 2016-06-02 2017-06-02 Pharmaceutical formulation comprising cineol and amoxicillin
EA201892808A EA201892808A1 (en) 2016-06-02 2017-06-02 PHARMACEUTICAL PREPARATION, INCLUDING CINEOL AND AMOXICILLIN
US18/408,636 US20240148702A1 (en) 2016-06-02 2024-01-10 Pharmaceutical formulation comprising cineole and amoxicillin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MA39085A MA39085B1 (en) 2016-06-02 2016-06-02 Combination of cineol and amoxicillin for use in the treatment of a bacterial infection

Publications (2)

Publication Number Publication Date
MA39085A1 MA39085A1 (en) 2017-12-29
MA39085B1 true MA39085B1 (en) 2018-06-29

Family

ID=61167677

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39085A MA39085B1 (en) 2016-06-02 2016-06-02 Combination of cineol and amoxicillin for use in the treatment of a bacterial infection

Country Status (2)

Country Link
EA (1) EA201892808A1 (en)
MA (1) MA39085B1 (en)

Also Published As

Publication number Publication date
MA39085A1 (en) 2017-12-29
EA201892808A1 (en) 2019-05-31

Similar Documents

Publication Publication Date Title
EA201991523A1 (en) COMBINED THERAPY BY AMIDINE-SUBSTITUTED BETA-LACTAMIC COMPOUNDS AND INHIBITORS OF BETA-LACTAMASE IN INFECTIONS CAUSED BY BACTERIAL STRAINS RESISTANT TO ANTIBIOTICS
MA41013A (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
MX362683B (en) Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor.
EP4151228A3 (en) Lysin polypeptides active against gram-negative bacteria
MA32025B1 (en) Beta-lactamase inhibitors
PH12019500558A1 (en) Beta-lactamase inhibitor compounds
BR112013032711A2 (en) pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
BR112017010132A2 (en) combination therapy for treatment of resistant bacterial infections
FR3029790B1 (en) CHITOSAN HYDROGEL MICROBELL
RU2015102562A (en) PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING MASTITIS
WO2015046505A8 (en) Anti-lps o11 antibody
WO2021022163A3 (en) Compounds and uses thereof
ZA202006612B (en) Antibacterial compounds
WO2017218922A3 (en) Compositions and methods for the treatment of bacterial infections
EP3860619A4 (en) Compositions and methods for the treatment of pathogenic infections in plants
EP4268897A3 (en) Minocycline compounds for biodefense
EP4272831A3 (en) Diazabicyclooctanones as inhibitors of serine beta-lactamases
MX2022006109A (en) 1-aminosulfonyl-2-carboxypyrrole derivatives as metallo-beta-lactamase inhibitors.
WO2014165126A3 (en) Derivatized 3-styryl-cephalosporins
NZ706734A (en) Pharmaceutical compositions useful for the treatment or control of bacterial infections
PH12019500331A1 (en) Beta-lactamase inhibitors
MA39085B1 (en) Combination of cineol and amoxicillin for use in the treatment of a bacterial infection
MX2018011095A (en) Carbapenem compounds.
PH12020550222A1 (en) Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections
MA40844A (en) LONG-ACTING PHARMACEUTICAL COMPOSITIONS FOR HEPATITIS C